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The extent of lymphadenectomy for the curative treatment
of gastric cancer has been subject to considerable debate
over the past decades. Despite a plethora of retrospective
and single-institution studies comparing different types of
lymphadenectomy, only a limited number of randomized
controlled trials have focused on this subject. Recently,
Tanizawa et al. [1] published an extensive review of
existing evidence on lymph node dissection in gastric
cancer. This comprehensive review discusses several
aspects of lymphadenectomy, including limited versus
extended lymphadenectomy, dissection of para-aortal
lymph nodes, routine splenectomy and pancreatectomy,
and lymph node dissection for early gastric cancer. How-
ever, shortly after the review was accepted several relevant
and important studies on gastric cancer surgery were
published. In the current letter, we wish to give a European
perspective on the extent of lymphadenectomy that should
be recommended for advanced, resectable gastric cancer,
and reﬂect on several more recent developments.
Shortly after ﬁnishing accrual of the Dutch Gastric
Cancer Group trial comparing D1 with D2 lymphadenec-
tomy, morbidity and mortality results were published,
indicating signiﬁcantly higher mortality after a D2 dissec-
tion (10 vs. 4%) [2], similar to the Medical Research
Council Gastric Cancer trial [3]. The number of splenec-
tomies and pancreatectomies, which have shown to
increase postoperative mortality, were also higher in the D2
group. Analyses performed after 11 and 15 years of follow-
up revealed no signiﬁcant differences in overall survival [4,
5]. However, when analyzing cause-speciﬁc death at
15 years, gastric cancer-related death was signiﬁcantly
lower after a D2 (37%) when compared to a D1 (48%)
dissection (P = 0.01) [5], suggesting that when postoper-
ative mortality can be avoided, D2 lymphadenectomy
improves survival after a gastric cancer resection. A more
recent Italian study analyzed D1 versus D2 lymphadenec-
tomy in 267 patients treated in ﬁve centers [6]. Although
long-term survival results have to be awaited, and the study
population might be too small to detect minor differences
in overall survival, postoperative mortality after a D2 dis-
section was only 2.2%. This taken together with the cur-
rently performed spleen-preserving gastrectomy indicates
that D2 lymph node dissection in experienced centers
should be the recommended type of surgery in advanced
gastric cancer, also in the Western part of the world.
Avoiding postoperative mortality is a major challenge in
gastrectomy, especially when performed in lower volumes
like in many European countries. Whereas Japan has
established national screening programs for gastric cancer,
and has a two- to seven-fold higher incidence rate as
compared to European countries, in Europe incidence rates
are relatively low, leading to lower exposure of hospitals to
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domized studies can signiﬁcantly improve outcome over a
longer period [7], increasing the surgeons’ and hospital
exposure is the key to improvement in treatment results
after low-volume high-risk surgery such as gastrectomy.
Many studies have explored the relation between hospital
volume and outcome and found that increasing surgeons’
and hospital volume is associated with lower postoperative
mortality and higher survival rates, both in the Western
world and in Asia [8]. In Denmark, this has led to enforced
centralization of gastric cancer surgery from 37 to 5 hos-
pitals as of 2003, which has resulted in a signiﬁcant
decrease in postoperative mortality (8.2% in 2003 to 2.4%
in 2008, P\0.05) and an increase in the number of
patients with at least 15 lymph nodes examined (19–67%)
[9]. Centralization of gastric cancer surgery is currently
implemented in the UK, Sweden, Finland, and in certain
regions in the Netherlands. An additional strategy towards
improvement of care is auditing. With auditing, surgeons
can improve their results by learning from their own out-
come statistics benchmarked against their peers, which is
often referred to as the Hawthorne effect. Among other
variables of interest, in gastric cancer surgery auditing
provides the opportunity to analyze differences in hospital
mortality, the extent of lymph node dissection, and the use
of laparoscopic techniques. Auditing has proven its value
in rectal cancer treatment in Europe [10], and audits for
gastric and esophageal cancer are currently present in
Denmark, the UK, and the Netherlands.
Meanwhile, the question remains how to treat patients
who have undergone suboptimal (D1 or less) surgery for
gastric cancer. As the majority of patients in the Intergroup
0116 trial underwent a D0 or D1 dissection, postoperative
chemoradiotherapy can be considered to signiﬁcantly
improve survival in these patients [11]. However, in a
separate report, the investigators of the Intergroup 0116
trial concluded that D-level designation failed to signiﬁ-
cantly correlate with survival, although the power to detect
such interaction was low [12]. A more recent report,
comparing patients treated in the Dutch Gastric Cancer
Group trial (who only underwent surgery) with patients
treated in several Dutch phase I/II studies with postopera-
tive ﬂuoropyrimidine-based chemoradiotherapy, showed a
signiﬁcant association between postoperative chemoradio-
therapy use and improved local control and overall survival
after a D1 dissection, but not after a D2 dissection [13].
Also, chemoradiotherapy was highly associated with
improved survival after a microscopically irradical (R1)
resection. A regimen with capecitabine, cisplatin, and
radiotherapy that emerged from the phase I/II studies is
currently tested in the international, multicenter phase III
CRITICS trial (ChemoRadiotherapy after Induction Che-
moTherapy in Cancer of the Stomach). In this trial,
perioperative chemotherapy, which proved its value in the
MAGIC study [14], is compared with preoperative che-
motherapy combined with postoperative chemoradiation
[15]. The chemotherapy regimen consists of epirubicin,
cisplatin, and capecitabine. For surgery, an extended lym-
phadenectomy without splenectomy should be performed.
Currently participating countries are the Netherlands,
Sweden, and Denmark. While a total of 788 patients are
needed for this study, accrual as of July 2011 is 367 (47%).
In conclusion, D2 lymphadenectomy is the recom-
mended type of surgery for advanced, resectable gastric
cancer in the Western world. Especially when performed in
experienced centers with low postoperative mortality,
extended lymphadenectomy brings considerable beneﬁt in
terms of gastric cancer-related death. Nationwide initia-
tives, such as concentration and auditing, can further
improve gastric cancer care.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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